25.21
-0.38 (-1.50%)
| Previous Close | 25.60 |
| Open | 25.58 |
| Volume | 2,015,309 |
| Avg. Volume (3M) | 1,204,816 |
| Market Cap | 1,841,298,048 |
| Price / Sales | 9.29 |
| Price / Book | 4.60 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 - 5 May 2025 |
| Profit Margin | -90.16% |
| Operating Margin (TTM) | -23.45% |
| Diluted EPS (TTM) | -2.57 |
| Quarterly Revenue Growth (YOY) | 19.10% |
| Total Debt/Equity (MRQ) | 27.96% |
| Current Ratio (MRQ) | 3.31 |
| Operating Cash Flow (TTM) | -157.37 M |
| Levered Free Cash Flow (TTM) | -201.95 M |
| Return on Assets (TTM) | -16.09% |
| Return on Equity (TTM) | -38.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Schrodinger, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 5.0 |
| Average | 0.20 |
|
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 2.49% |
| % Held by Institutions | 97.91% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gates Foundation Trust | 31 Dec 2024 | 6,981,664 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (Piper Sandler, 78.50%) | Buy |
| Median | 38.50 (52.72%) | |
| Low | 32.00 (Keybanc, 26.93%) | Buy |
| Average | 38.50 (52.72%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 23.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Keybanc | 16 Apr 2025 | 32.00 (26.93%) | Buy | 24.38 |
| Piper Sandler | 27 Feb 2025 | 45.00 (78.50%) | Buy | 22.25 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AKINSANYA KAREN | - | 26.54 | -16,723 | -443,828 |
| Aggregate Net Quantity | -16,723 | |||
| Aggregate Net Value ($) | -443,828 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 26.54 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AKINSANYA KAREN | Officer | 14 Apr 2025 | Automatic sell (-) | 16,723 | 26.54 | 443,828 |
| AKINSANYA KAREN | Officer | 14 Apr 2025 | Option execute | 16,723 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |